I. Introduction

The Drug Has No Address

Cancer pharmacology has produced remarkable molecules agents capable of halting cell division, triggering apoptosis, and dismantling tumors at the molecular level. Yet outcomes for many solid tumor cancers remain poor, not because the drugs fail chemically, but because they never arrive in sufficient concentration at the place they are needed.

Systemic chemotherapy floods the entire body. The drug circulates through the liver, kidneys, heart, and gut with no preferential accumulation at the tumor. The tumor is reached only incidentally by diffusion and the leakiness of tumor vasculature not by design.

These are not edge-case failures. They are the median outcome across more than a century of oncology. The drugs work. The delivery doesn't.

II. Background

Why Passive Targeting Fails

The dominant passive targeting strategy exploits the Enhanced Permeability and Retention (EPR) effect tumor blood vessels are abnormally leaky, allowing nanoparticles to accumulate over time. In preclinical mouse models this produces measurable results. In human patients, results have been inconsistent.

Human tumors show enormous variability in vasculature, interstitial pressure, and stromal composition. A passive system cannot adapt to that variability. It drifts toward wherever the body's fluid dynamics take it, which is rarely the tumor.¹

The EPR effect is real but it is not an engineering solution. It is a coincidence we have been trying to exploit for decades with diminishing returns. The problem requires active targeting a system that swims toward the tumor, not one that waits to drift there.

III. Approach

Active Delivery via Biohybrid Microrobots

Project Avaia proposes an active delivery solution: a living microorganism that swims autonomously, enhanced with synthetic components that make it magnetically steerable and drug-loaded. The design has four layers.

• 1 The biological chassis — Chlamydomonas reinhardtii A single-celled green alga, 10–22 μm in diameter, propelled by two flagella at approximately 120 μm/s. Non-pathogenic, FDA-recognized as safe, with a fully sequenced genome. Naturally accumulates in low-oxygen environments the same hypoxic gradients that characterize solid tumors.
• 2 The magnetic layer — Fe₃O₄ nanoparticles Iron oxide nanoparticles bind electrostatically to the algae cell surface, forming a magnetic shell without impairing cell viability or motility. This makes the cell responsive to external magnetic fields for directional steering.²
• 3 The drug payload Therapeutics are attached to the nanoparticle layer. Release is triggered by the acidic pH of the tumor microenvironment (pH 6.5–6.9), which destabilises the carrier at the target site. The payload remains dormant in transit.
• 4 Magnetic steering — custom electromagnet arrays Custom-wound coil arrays driven by programmable current controllers generate directed fields to navigate the bots. The algae provides thrust. The field provides direction.

The key insight is that biology already solved the propulsion problem. C. reinhardtii navigates fluid environments at scales where most engineered microrobots cannot function efficiently. We are not replacing the organism. We are giving it a destination.

IV. Data

Delivery Efficiency Across Approaches

The gap between passive and active delivery is not marginal. Across the literature, biohybrid microrobot delivery shows roughly a 17x improvement over standard nanoparticle approaches not in a single optimistic study, but as an emerging pattern across in vivo murine models.

The motility data is also encouraging. Coating the algae with Fe₃O₄ at optimal density below 15% surface coverage shows minimal reduction in swimming speed. The organism remains functional as a propulsion system while gaining magnetic steerability.

The critical caveat is that all biohybrid microrobot results to date are in murine models. Human tumor microenvironments are significantly more complex. Translation is unproven. That is what makes it worth building toward.

V. Build Pipeline

What We Are Actually Building

This is an independent research project built outside any institutional setting. No lab access, no university grant, no supervisor. The fabrication pipeline is being developed from scratch, with full control over every variable.

The immediate goal is demonstrating magnetic steering of Fe₃O₄-coated algae under a custom electromagnet array showing that motility is preserved and direction can be controlled. Everything downstream depends on that proof of concept.

Most people working on targeted drug delivery come from either pure biology or pure engineering. The problem sits exactly at the boundary. That is where this project lives, and where I think the real leverage is.